Medically reviewed by Dr. Tom Biernacki, DPM — Board-Certified Podiatric Surgeon — Balance Foot & Ankle, Howell & Bloomfield Hills, MI. Last updated April 2026.

Quick Answer

Psoriatic arthritis affects the feet in up to 40% of patients, causing painful joint inflammation, sausage-like toe swelling (dactylitis), Achilles tendon inflammation (enthesitis), nail changes, and skin plaques. Early diagnosis and treatment by a podiatrist working alongside a rheumatologist prevents permanent joint damage. Treatment combines systemic medications with local foot care including supportive orthotics, topical pain relief, and protective footwear.

Medical Review

Medically reviewed by Dr. Thomas Biernacki, DPM — Board-certified podiatrist at Balance Foot & Ankle, Southeast Michigan. Dr. Biernacki diagnoses and manages the foot and ankle manifestations of psoriatic arthritis, coordinating care with rheumatologists for comprehensive disease management.

Affiliate disclosure: This page contains affiliate links to products we recommend. We may earn a small commission at no extra cost to you. We only recommend products used in our clinical practice.

Table of Contents

• What Is Psoriatic Arthritis?
• How Psoriatic Arthritis Affects the Feet
• Dactylitis: Sausage Toes
• Enthesitis: Achilles and Plantar Fascia Inflammation
• Nail Changes in Psoriatic Arthritis
• Joint Erosion and Deformity
• Diagnosing Psoriatic Arthritis in the Feet
• Systemic Treatment Options
• Local Foot Care Strategies
• Orthotic Support for Psoriatic Arthritis
• Topical Pain Relief
• Compression for Swelling Management
• Choosing Footwear With Psoriatic Arthritis
• Managing Foot Flares
• Most Common Mistake
• Warning Signs of Disease Progression
• Foot Skin Care With Psoriasis
• Video Guide
• Frequently Asked Questions
• Sources
• Book an Appointment

What Is Psoriatic Arthritis?

Psoriatic arthritis (PsA) is a chronic inflammatory autoimmune disease that affects approximately 30% of people with psoriasis. The immune system mistakenly attacks healthy joint tissue, causing inflammation, pain, swelling, and progressive joint damage. Unlike osteoarthritis, which results from mechanical wear and tear, psoriatic arthritis is driven by systemic immune dysregulation and can affect joints, tendons, ligaments, and the entheses (where tendons and ligaments attach to bone).

The disease has a strong genetic component, with multiple genes in the HLA system contributing to susceptibility. However, environmental triggers — including infections, physical trauma, and psychological stress — often precede disease onset. In approximately 15% of cases, joint symptoms appear before any skin manifestation of psoriasis, making initial diagnosis challenging. These patients may be misdiagnosed with rheumatoid arthritis, gout, or other arthropathies until characteristic skin or nail changes develop.

Psoriatic arthritis follows five recognized clinical patterns: distal interphalangeal predominant (affecting the joints closest to the nails), asymmetric oligoarthritis (affecting fewer than five joints unevenly), symmetric polyarthritis (resembling rheumatoid arthritis), axial disease (affecting the spine and sacroiliac joints), and arthritis mutilans (a rare, severely destructive form). Most patients experience a combination of these patterns over the course of their disease, and the pattern may shift over time.

The feet are among the most commonly and earliest affected sites in psoriatic arthritis. A podiatrist may be the first clinician to identify PsA in patients presenting with unexplained foot pain, toe swelling, heel pain, or nail changes. Early recognition and referral to rheumatology for systemic treatment can prevent irreversible joint damage that occurs in up to 40% of patients within the first two years of untreated disease.

How Psoriatic Arthritis Affects the Feet

The feet are a primary target of psoriatic arthritis because they contain numerous joints, entheses, and tendons that are all susceptible to the inflammatory process. The mechanical stress of weight-bearing may actually contribute to disease activity in the feet — a phenomenon known as deep Koebner response, where physical trauma triggers an immune response at the site of stress. This may explain why the feet are disproportionately affected compared to similar joints in the hands.

Foot involvement in PsA typically manifests through several distinct but overlapping presentations. Joint synovitis causes swelling, warmth, and stiffness in the toe joints, particularly the distal interphalangeal joints (closest to the nails) and the metatarsophalangeal joints (where the toes meet the foot). The midfoot joints (tarsometatarsal and naviculocuneiform) can also be affected, causing deep aching pain across the arch that worsens with walking.

Morning stiffness lasting more than 30 minutes is a hallmark of inflammatory arthritis and helps distinguish PsA from mechanical foot problems. Patients typically describe their feet as feeling “frozen” upon waking, requiring extended warm-up periods before they can walk comfortably. This stiffness may also occur after prolonged sitting or inactivity during the day — a phenomenon called “gelling.”

Foot pain in PsA tends to wax and wane in flares, with periods of significant inflammation alternating with relative quiescence. Flares may be triggered by stress, illness, weather changes, or medication adjustments. The unpredictable nature of flares makes daily planning challenging for many patients and contributes to the significant quality-of-life impact of foot-predominant PsA.

Dactylitis: The Hallmark Sausage Toe

Dactylitis — diffuse swelling of an entire digit that gives it a sausage-like appearance — is considered the hallmark feature of psoriatic arthritis and is present in up to 50% of patients at some point during their disease course. Unlike the focal joint swelling seen in rheumatoid arthritis, dactylitis involves inflammation of the entire digit including the joint synovium, the flexor tendon sheath, the surrounding soft tissue, and the entheses.

In the feet, dactylitis most commonly affects the second and third toes, though any toe can be involved. The affected toe becomes uniformly swollen, red, warm, and exquisitely painful. The swelling extends the full length of the toe, distinguishing it from isolated joint swelling or tendon sheath inflammation. During active dactylitis, the toe may be too painful and swollen to fit comfortably in a shoe, significantly limiting mobility.

Dactylitis has important prognostic implications. Research shows that toes affected by dactylitis are at significantly higher risk of developing erosive joint damage compared to non-dactylitic digits. Recurrent dactylitis in the same digit can lead to permanent swelling even between flares, as chronic inflammation causes fibrosis and remodeling of the soft tissues. Aggressive systemic treatment of dactylitis — particularly with biologic medications targeting TNF-alpha or IL-17 — can prevent this progression.

Enthesitis: Achilles and Plantar Fascia Inflammation

Enthesitis — inflammation at the sites where tendons and ligaments insert into bone — is another distinguishing feature of psoriatic arthritis that frequently manifests in the feet. The Achilles tendon insertion at the back of the heel and the plantar fascia insertion at the bottom of the heel are the two most commonly affected entheses in PsA patients. This presentation is often the first symptom of psoriatic arthritis, preceding joint involvement by months or even years.

Achilles enthesitis in PsA causes pain, swelling, and tenderness at the back of the heel where the Achilles tendon attaches to the calcaneus. Unlike mechanical Achilles tendinitis (which typically affects the mid-substance of the tendon), PsA enthesitis is focused specifically at the bone-tendon junction. MRI imaging often reveals bone marrow edema at the calcaneal insertion — a finding that distinguishes inflammatory enthesitis from mechanical tendinopathy.

Plantar fascia enthesitis presents as heel pain that can be clinically indistinguishable from common plantar fasciitis. However, several features suggest an inflammatory cause: bilateral involvement (both heels simultaneously), morning stiffness lasting more than 30 minutes, pain that improves rather than worsens with initial activity, symptoms that began without a change in activity level or footwear, and the presence of other PsA features like nail pitting or skin plaques. Patients with “plantar fasciitis” that does not respond to standard conservative treatment should be evaluated for an underlying inflammatory arthropathy.

Treatment of enthesitis in PsA typically requires systemic therapy rather than local measures alone. While corticosteroid injections provide temporary relief, they do not address the underlying immune dysregulation and repeated injections at tendon insertions may weaken the tendon-bone interface. Biologic medications, particularly IL-17 inhibitors (secukinumab, ixekizumab) and IL-23 inhibitors (guselkumab, risankizumab), have shown particular efficacy for enthesitis in clinical trials.

Nail Changes in Psoriatic Arthritis

Nail involvement occurs in approximately 80% of PsA patients and serves as an important diagnostic clue. The nail matrix and nail bed share an anatomical connection with the distal interphalangeal (DIP) joint, which explains why nail changes are so strongly associated with DIP joint arthritis. In fact, nail dystrophy in the setting of psoriasis is one of the strongest predictors of developing psoriatic arthritis.

Nail pitting — small, punctate depressions on the nail surface — is the most common finding, resulting from focal inflammation in the proximal nail matrix. Onycholysis (separation of the nail from the nail bed) occurs when inflammation disrupts the attachment between the nail plate and underlying tissue. Oil spots — yellowish-brown discolorations visible through the nail — represent inflammatory exudate trapped between the nail bed and nail plate. Subungual hyperkeratosis (thickening of tissue under the nail) occurs as the nail bed produces excess keratin in response to chronic inflammation.

Toenail changes in PsA are often misdiagnosed as fungal nail infection (onychomycosis) because both conditions cause nail thickening, discoloration, and dystrophy. Distinguishing features of PsA nails include nail pitting (not seen in fungal infections), associated skin plaques or joint symptoms, and negative fungal cultures. Importantly, PsA patients can also have concurrent fungal infections, so a positive fungal culture does not rule out PsA as a contributing cause of nail dystrophy.

Joint Erosion and Deformity

Without adequate treatment, psoriatic arthritis causes progressive erosion of cartilage and bone within affected joints. In the feet, this erosive process most commonly affects the DIP joints, MTP joints, and interphalangeal joint of the great toe. Radiographic changes include joint space narrowing, marginal erosions, periostitis (new bone formation along the shaft), and in severe cases, the characteristic “pencil-in-cup” deformity where the distal bone is resorbed into a point that sits within an expanded proximal bone.

Joint damage in PsA is irreversible once established. Erosions that develop during periods of uncontrolled inflammation permanently alter joint mechanics and can cause progressive deformity. This is why early, aggressive treatment of PsA is so critical — the window of opportunity to prevent structural damage is limited to the first one to two years of active disease. Patients treated with biologic medications within this window show significantly less radiographic progression than those treated later.

Toe deformities resulting from PsA include hammer toes, claw toes, crossover toes, and hallux valgus (bunion). These deformities create abnormal pressure points that predispose to calluses, corns, and ulceration. In severe cases, the MTP joints can subluxate or dislocate, causing the fat pad that normally cushions the ball of the foot to shift forward, leaving the metatarsal heads exposed and painful during weight bearing.

Diagnosing Psoriatic Arthritis in the Feet

Diagnosis of PsA relies on clinical assessment, imaging, and laboratory testing. The CASPAR criteria (Classification Criteria for Psoriatic Arthritis) provide a validated framework: the patient must have inflammatory articular disease plus at least three points from the following — current psoriasis (2 points), personal or family history of psoriasis (1 point), nail dystrophy (1 point), dactylitis (1 point), negative rheumatoid factor (1 point), or radiographic evidence of juxta-articular new bone formation (1 point).

In the feet, X-rays may show the characteristic erosive pattern of PsA, including pencil-in-cup deformity, periostitis, and new bone formation that distinguishes it from rheumatoid arthritis. Ultrasound is increasingly used for early diagnosis because it can detect subclinical enthesitis, synovitis, and tendon sheath inflammation before they become clinically apparent. Power Doppler ultrasound reveals the increased blood flow associated with active inflammation, helping to guide treatment decisions.

MRI provides the most comprehensive assessment of foot involvement in PsA, revealing bone marrow edema, synovitis, enthesitis, dactylitis, and tenosynovitis with excellent sensitivity. MRI is particularly valuable for detecting early disease before erosive changes appear on X-rays. In patients with heel pain suspicious for inflammatory enthesitis, MRI demonstrating bone marrow edema at the calcaneal insertion of the Achilles or plantar fascia strongly supports an inflammatory diagnosis.

Systemic Treatment Options

Systemic treatment of psoriatic arthritis is managed by a rheumatologist and is essential for controlling the immune dysregulation that drives joint and tendon inflammation. The treatment landscape has been revolutionized by biologic medications that target specific cytokines involved in the PsA inflammatory cascade.

Conventional disease-modifying antirheumatic drugs (DMARDs) like methotrexate, sulfasalazine, and leflunomide remain first-line systemic therapy for many patients with mild to moderate PsA. Methotrexate is the most commonly prescribed, with evidence supporting its efficacy for peripheral joint disease and skin involvement. However, conventional DMARDs have limited efficacy for enthesitis and axial disease.

Biologic medications represent a significant advance in PsA treatment. TNF-alpha inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab) were the first biologics approved for PsA and remain effective for joint, skin, and entheseal disease. IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab) show particular efficacy for enthesitis and dactylitis. IL-23 inhibitors (guselkumab, risankizumab) offer another mechanism with strong efficacy for both skin and joint disease. JAK inhibitors (tofacitinib, upadacitinib) provide oral biologic-equivalent efficacy for patients who prefer non-injectable options.

Local Foot Care Strategies

While systemic treatment controls the underlying disease process, local foot care addresses the day-to-day pain, function, and comfort that directly impact quality of life. A podiatrist plays a critical role in the multidisciplinary management team for PsA patients with foot involvement, providing interventions that complement systemic therapy.

Gentle range-of-motion exercises performed daily help maintain joint flexibility in affected toes. Toe spreads, marble pickups, towel curls, and alphabet exercises with the foot keep the intrinsic muscles active and prevent stiffness-related contractures. Exercises should be performed when joints are warm and loosened — after a warm bath or shower is ideal. During active flares, exercise intensity should be reduced to gentle range of motion only, avoiding any movements that increase pain or swelling.

Corticosteroid injections can provide targeted relief for acutely inflamed foot joints. Ultrasound-guided injection of a corticosteroid into a swollen MTP joint or inflamed tendon sheath can rapidly reduce pain and swelling during a flare. However, repeated injections into the same site should be limited (typically no more than three per year) to avoid weakening surrounding tissues. Joint injections work best as a bridge therapy while systemic medications are being optimized.

Orthotic Support for Psoriatic Arthritis

Orthotics serve a dual purpose in PsA: redistributing weight away from inflamed joints and providing cushioning that absorbs the impact forces of walking. For patients with MTP joint involvement, orthotics with metatarsal pads positioned proximal to the metatarsal heads offload the painful joints and allow more comfortable weight bearing.

We recommend PowerStep Pinnacle Insoles for PsA patients who need daily arch support and cushioning. The structured arch support stabilizes the midfoot joints that are often affected by PsA inflammation, while the cushioned forefoot and heel absorb impact that would otherwise be transmitted through painful joint surfaces. The semi-rigid design provides enough structure to support compromised joints without being so rigid that it restricts the gentle movement needed to prevent stiffness.

For patients with significant deformity or severe joint erosion, custom orthotics with total-contact accommodative design provide superior pressure redistribution. These devices are fabricated from softer materials that conform to the foot’s altered shape, cradling deformed joints and distributing weight across the entire plantar surface. Depth shoes with extra volume accommodate both the custom orthotic and the increased foot width that develops as joints swell and deform over time.

Topical Pain Relief for Inflamed Joints

Topical pain relief provides localized comfort for inflamed foot joints without the systemic side effects of oral medications. This is particularly valuable for PsA patients who may already be taking multiple systemic medications and want to minimize additional oral drug burden.

We recommend Doctor Hoy’s Natural Pain Relief Gel for PsA patients managing daily foot pain. The natural menthol and camphor formula provides cooling relief when applied over swollen toe joints, painful Achilles insertions, or inflamed plantar fascia. Apply to intact skin over affected areas before putting on shoes in the morning and again in the evening after removing footwear. The clean, non-irritating formula is important for PsA patients whose skin may already be sensitive from psoriatic plaques in the affected areas.

Topical NSAID gels (diclofenac gel/Voltaren) offer another option for localized anti-inflammatory relief. Applied directly over inflamed joints, topical NSAIDs achieve therapeutic concentrations in the underlying tissue with minimal systemic absorption. They can be used as an adjunct to topical pain relief gels for multi-layered symptom management during flares.

Compression for Swelling Management

Foot and ankle swelling is a persistent problem for many PsA patients, driven by both joint inflammation and the generalized edema that accompanies systemic inflammatory disease. Compression therapy helps manage this swelling, improving comfort and supporting daily function.

We recommend DASS Compression Socks for PsA patients managing chronic foot and ankle swelling. Graduated compression promotes fluid return from the lower extremities and reduces the tissue edema that contributes to joint stiffness and pain. Wearing compression socks during the day helps maintain foot volume and makes shoes fit more consistently — a common challenge for PsA patients whose foot swelling fluctuates throughout the day and between flares.

During active flares with severe swelling, gentle compression may need to be reduced or temporarily discontinued if it causes increased pain in acutely inflamed joints. Listen to your body — compression should feel supportive, not painful. Resume full compression as the flare subsides and swelling begins to improve with systemic treatment adjustments.

Choosing Footwear With Psoriatic Arthritis

Footwear selection is critically important for PsA patients because ill-fitting shoes exacerbate joint pain, create pressure on deformities, and irritate psoriatic skin plaques. The ideal shoe has a wide, deep toe box that accommodates swollen toes without compression, a supportive but cushioned midsole, a seamless interior lining, and a rocker bottom sole that reduces forefoot bending forces during walking.

Avoid shoes with narrow toe boxes, high heels, or rigid materials that press against inflamed joints. Lace-up or adjustable-strap closures allow you to modify fit as swelling changes throughout the day. Consider purchasing shoes in the afternoon when feet are typically at their largest to ensure adequate room during periods of increased swelling.

For patients with significant deformity, extra-depth therapeutic shoes or custom-molded shoes may be necessary. These specialized shoes accommodate custom orthotics while providing enough volume for swollen, deformed feet. Medicare may cover therapeutic footwear for patients with PsA-related foot deformity under certain conditions — discuss eligibility with your podiatrist.

Managing Foot Flares

PsA flares — periods of increased disease activity — can be particularly debilitating when they affect the feet. Having a flare management plan in place before a flare occurs allows rapid response that minimizes pain and functional loss.

At the first sign of a flare (increasing pain, new swelling, morning stiffness exceeding your baseline), apply ice to inflamed joints for 15-20 minutes several times daily. Switch to your most accommodating footwear with maximum cushioning. Reduce walking distance and impact activities. Contact your rheumatologist about potential medication adjustments — a short course of oral corticosteroids or an adjustment in biologic dosing may be appropriate to bring the flare under control quickly.

Keep a flare diary tracking the timing, severity, affected joints, potential triggers, and response to interventions. This information helps your rheumatologist and podiatrist identify patterns, optimize treatment, and develop a personalized flare management strategy. Common triggers include respiratory infections, periods of high stress, significant weather changes, and missed medication doses.

Foot Skin Care With Psoriasis

Managing psoriatic skin plaques on the feet presents unique challenges because the soles are weight-bearing surfaces and the interdigital spaces are prone to moisture accumulation. Plantar psoriasis causes thick, scaling plaques on the soles that can crack painfully (fissures), while interdigital psoriasis creates macerated, peeling skin between the toes that is often mistaken for athlete’s foot.

Emollients are the foundation of foot skin care in psoriasis. Apply a thick, fragrance-free moisturizer (petroleum jelly, CeraVe, Eucerin) to the soles and heels immediately after bathing while the skin is still damp to lock in moisture. For thick plaques, keratolytic agents containing urea (20-40%) or salicylic acid (3-6%) soften and thin the scaling, improving penetration of topical medications and reducing fissure formation.

Keep the interdigital spaces dry by applying absorbent powder after bathing and wearing moisture-wicking socks. Avoid occlusive footwear that traps heat and moisture against psoriatic skin. Cotton or merino wool socks changed midday if feet become damp help maintain a healthy skin environment. Your dermatologist may prescribe topical corticosteroids, vitamin D analogs (calcipotriene), or topical retinoids for active foot plaques.

Video: Understanding Foot and Ankle Conditions

Watch Dr. Biernacki explain how inflammatory conditions affect the feet and the importance of early diagnosis and comprehensive treatment.

Frequently Asked Questions

Can psoriatic arthritis start in the feet?

Yes, psoriatic arthritis frequently presents first in the feet. Achilles enthesitis, plantar fascia enthesitis, dactylitis (sausage toe), and DIP joint inflammation are all common initial manifestations. In approximately 15% of PsA patients, joint symptoms appear before any skin psoriasis, making foot symptoms potentially the earliest sign of the disease. A podiatrist may be the first clinician to recognize these patterns and initiate appropriate referral.

How do I tell psoriatic arthritis apart from regular arthritis in my feet?

Key distinguishing features of PsA in the feet include dactylitis (entire toe swelling rather than just a joint), enthesitis (pain at tendon insertions like the Achilles), nail changes (pitting, onycholysis), morning stiffness lasting over 30 minutes, asymmetric joint involvement, and DIP joint predominance. Skin psoriasis anywhere on the body is a strong clue. Blood tests showing negative rheumatoid factor and imaging showing characteristic bone changes help confirm the diagnosis.

Will psoriatic arthritis permanently damage my feet?

Without treatment, PsA can cause permanent joint erosion, deformity, and loss of function in the feet. Up to 40% of untreated patients develop erosive joint damage within the first two years. However, modern biologic medications can halt disease progression and prevent new damage when started early. Early diagnosis and aggressive systemic treatment are the keys to preserving long-term foot function and preventing irreversible structural changes.

Can orthotics help with psoriatic arthritis foot pain?

Orthotics significantly improve daily comfort and function for PsA patients with foot involvement. Supportive insoles like PowerStep Pinnacle redistribute weight away from inflamed joints and provide cushioning that absorbs impact forces. Custom orthotics can be designed with metatarsal pads, arch support, and accommodative modifications to address specific joint involvement. Orthotics are most effective when combined with appropriate systemic medication and proper footwear.

Should I see a podiatrist or rheumatologist for psoriatic arthritis in my feet?

Both. A rheumatologist manages the systemic disease with medications that control the underlying immune dysregulation. A podiatrist manages the local foot manifestations with orthotics, footwear modifications, joint injections, nail care, skin management, and biomechanical optimization. The best outcomes occur when both specialists coordinate care to address psoriatic arthritis from both systemic and local perspectives simultaneously.

Sources

1. Ritchlin CT, et al. “Psoriatic Arthritis.” New England Journal of Medicine. 2017;376(10):957-970.
2. Coates LC, et al. “Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations.” Arthritis & Rheumatology. 2022;74(4):553-563.
3. Polachek A, et al. “The Association Between Sonographic Enthesitis and Radiographic Damage in Psoriatic Arthritis.” Arthritis Research & Therapy. 2017;19(1):189.
4. Gladman DD, et al. “Psoriatic arthritis: epidemiology, clinical features, course, and outcome.” Annals of the Rheumatic Diseases. 2005;64(suppl 2):ii14-ii17.
5. Turner DE, et al. “Interventions for the Foot in Psoriatic Arthritis: A Systematic Review.” Journal of Foot and Ankle Research. 2019;12:56.

Related Articles

• Rheumatoid Arthritis and the Feet
• Gout in the Foot: Treatment Guide
• Plantar Fasciitis Treatment Options
• Achilles Tendinitis Treatment
• Podiatrist Recommended Foot Care Products

When to See a Podiatrist for Psoriatic Arthritis Foot Symptoms

If psoriatic arthritis is affecting your feet with joint pain, swollen toes, or nail changes, a podiatrist can provide targeted treatment to maintain your mobility. At Balance Foot & Ankle, we manage autoimmune foot conditions at our Howell and Bloomfield Hills offices.

Learn About Our Arthritis Foot Care | Book Your Appointment | Call (810) 206-1402

Clinical References

1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. “Psoriatic arthritis: epidemiology, clinical features, course, and outcome.” Annals of the Rheumatic Diseases. 2005;64(Suppl 2):ii14-ii17.
2. Mease PJ, Armstrong AW. “Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.” Drugs. 2014;74(4):423-441.
3. Hyslop E, McInnes IB, Woodburn J, Turner DE. “Foot problems in psoriatic arthritis: high burden and low care provision.” Annals of the Rheumatic Diseases. 2010;69(5):928.